Keratinocytic Vascular Endothelial Growth Factor as a Novel Biomarker for Pathological Skin Condition.
10.4062/biomolther.2014.102
- Author:
Ok Nam BAE
1
;
Minsoo NOH
;
Young Jin CHUN
;
Tae Cheon JEONG
Author Information
1. College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 426-791, Republic of Korea. onbae@hanyang.ac.kr
- Publication Type:Review
- Keywords:
Vascular endothelial growth factor (VEGF);
Biomarker;
Keratinocytic damage;
Dermal toxicity
- MeSH:
Biomarkers;
Skin*;
Toxicity Tests;
Vascular Endothelial Growth Factor A*
- From:Biomolecules & Therapeutics
2015;23(1):12-18
- CountryRepublic of Korea
- Language:English
-
Abstract:
Skin is an emerging target tissue in pharmaceutical and cosmetic science. Safety assessment for dermal toxicity is a critical step for development of topically applicable pharmaceutical agents and ingredients in cosmetics. Urgent needs exist to set up toxicity testing methods for dermal safety, and identification of novel biomarkers for pathological cutaneous alteration is highly required. Here we will discuss if vascular endothelial growth factor (VEGF) has a potential as a biomarker for dermal impairment. Experimental and clinical evidences for induction of keratinocytic VEGF under pathological conditions will be reviewed.
